BioWorld Asia

March 19, 2003

For $55M, OSI Gets Novantrone U.S. Cancer Rights From Serono

Serono SA signed a licensing agreement with OSI Pharmaceuticals Inc., granting OSI exclusive rights to market and promote Novantrone in the U.S. in its approved oncology indications. (BioWorld International) Read More

OncoGenome Sciences Raises EUR14M For Cancer Diagnostics

New Drugs Could Flow From Bacterial Gene Cluster Variants

UroGene Second Round: EUR12M For Itself, Subsidiary Chrysalon

Riding Smallpox Contracts, Acambis Reports 2002 Profit

EU Worries More Biotechnology Companies Could Quit Europe

Entomed, Naeja Enter Two-Way Cancer, Infectious Diseases Deal

Potential OGS Buyers, CAT, Celltech, Jockey For Position

CellFactors Seeking £3.5M To Advance, Partner Skeletex

Products, Fundamentals Find Investor Favor In Down Market

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...